Acalabrutinib with bendamustine and rituximab is now an FDA-approved treatment for patients with previously untreated mantle ...

Objectives The RITUXVAS trial reported similar remission induction rates and safety between rituximab and cyclophosphamide based regimens for antineutrophil cytoplasm antibody (ANCA)-associated ...

Sergio A. Giralt, MD, discusses how rituximab plays a key role in treating chronic graft-vs-host disease. It is often used in combination with ibrutinib to enhance therapeutic outcomes. He reviews the ...

The FDA approved acalabrutinib in combination with bendamustine and rituximab for adults with previously untreated mantle ...

Twenty-four hour albuminuria decreased from a mean of 5.0 g/day (2.4–7.1) to 1.2 (0.0–4.0) (p=0.023). In five patients evaluated, all had complete peripheral blood B-cell depletion as defined, after ...

Sue loves to run. In fact, it's exactly what she was doing when she realised something was wrong."I started to get really ...

An investigational induced pluripotent stem cell-derived CAR natural killer cell therapy was well tolerated both as ...

The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...

She was admitted to hospital as an emergency with prolonged and painful extensor spasms affecting the neck and back, arms, and legs. The disease had progressed despite a favourable initial response to ...